Table 3.
Long-Term Outcome of Patients Undergoing Noncurative ER for EGCs (≥100 Cases)
| Author (year) | Country | No. of patients | No additional treatment, % | Median follow-up period, mo | Additional surgery, % | No additional treatment, % | ||
|---|---|---|---|---|---|---|---|---|
| 5-yr OS | 5-yr DSS | 5-yr OS | 5-yr DSS | |||||
| Hatta et al. (2017)55 | Japan | 1,969 | 45.5 | 66 | 92.6 | 98.8 | 75.2 | 97.5 |
| Suzuki et al. (2017)57 | Japan | 540 | 35.6 | 76*, 70† | 94.7 | 98.8 | 83.8 | 96.8 |
| Kawata et al. (2017)58 | Japan | 506 | 36.2 | 65*, 61† | 90.0 | 98.7 | 72.0 | 96.5 |
| Kim et al. (2015)60 | Korea | 274 | 29.2 | 60.5 | 94.3 | 99.5‡ | 85.0 | 97.0‡ |
| Yang et al. (2015)56 | Korea | 267 | 53.9 | 40.7 | NA | 98.7 | NA | 97.4 |
| Yano et al. (2018)61 | Japan | 231 | 48.9 | 48 | 96.0 | 100 | 73.3 | 92.6 |
| Kikuchi et al. (2017)59 | Japan | 150 | 51.3 | 4.8 yr*, 4.7 yr† | 85.0 | 97.0§ | 79.4 | 95.3§ |
ER, endoscopic resection; EGC, early gastric cancers; OS, overall survival; DSS, disease-specific survival; NA, no assessment.
*
In patients with additional surgery after endoscopic submucosal dissection (ESD) with noncurative resection; †In patients with no additional treatment after ESD with noncurative resection; ‡Total survival rate; §Recurrence-free survival.